A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer
The goal of this study is to determine the efficacy and safety of camrelizumab given concomitantly with chemoradiation in participants with unresectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). All participants will receive camrelizumab in addition to chemoradiation, the standard treatment for LA-HNSCC.
Head and Neck Neoplasms
BIOLOGICAL: Camrelizumab|DRUG: Cisplatin|RADIATION: IMRT or VMAT
Objective Response Rate, The number of participants with radiologically confrmed complete or partial response according to RECIST 1.1, 6 months
Overall Survival (OS), OS is the time from randomization to death due to any cause., Up to 5 years|Disease-free Survival (DFS), DFS is the time from the date of randomization to the date of first record of disease recurrence or death., Up to 5 years|Acute Adverse Events (AEs), The number of participants who experience unacceptable toxicity during protocol treatment as measured by the NCI CTCAE version 4.0, Up to 6 months
The goal of this study is to determine the efficacy and safety of camrelizumab given concomitantly with chemoradiation in participants with unresectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). All participants will receive camrelizumab in addition to chemoradiation, the standard treatment for LA-HNSCC.